Why Is This Research Study Being Conducted?
* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
Age ≥18 years
Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms
Eastern Cooperative Oncology Group (ECOG) performance status ≤3
Expected survival of at least 6 months
Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis
Hematopoietic stem cell transplantation expected within 6 months
All patients with MDS diagnosed and treated at UVMMC will be eligible.
Case-only
Prospective
Observational
Other interventionBlood will be collected from one cohort to identify potential blood biomarkers.
Biologic Variability of Markers of Inflammation in the Blood
The within- and between-person biologic variability of an inflammation proteome over a period of 6 months
Click on the lead sponsor to view all of their trials.
